News from the web:
Read all about it HERE
visit us at AlzheimerHeadlines.com
News from the web:
Charles Snelling spent six years taking care of his Alzheimer’s-stricken wife, Adrienne, helpless as he watched the disease steal his college sweetheart. In March, after six decades of marriage, Snelling killed his longtime partner, and then he killed himself. Both were 81. “After apparently reaching the point where he could no longer bear to see the love of his life deteriorate further, our father ended our mother’s life and then took his own life as well,” his children said in a statement. “This is a total shock to everyone in the family, but we know he acted out of deep devotion and profound love.”
Indeed, Alzheimer’s disease unleashes a devastating, sometimes unmanageable burden. It is a leading cause of disability and death, with numbers poised to explode in coming years as the older population grows. (Symptoms typically first appear after age 60.) By 2050, an estimated 16 million people will be diagnosed with Alzheimer’s, the most common type of dementia, and roughly 5.4 million Americans are currently living with the condition, according to a March report by the Alzheimer’s Association, a nonprofit advocacy group. One person develops Alzheimer’s every second. It’s the 6th leading cause of death in the United States, and the 5th for those age 65 and older. And there’s no cure. “We should be very worried,” says Reisa Sperling, director of the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital in Boston.
Read all about it HERE
visit us at AlzheimerHeadlines.com
News from the web:
Henry Dryer sits slumped over the tray attached to his wheelchair. He doesn’t speak, and rarely moves, until a nursing home worker puts his headphones on.
Then Dryer’s feet start to shuffle, his folded arms rock back and forth, and he sings out loud in perfect sync with his favorite songs.
“I feel a band of love, dreams,” said Dryer, 92, who has dementia. “It gives me the feeling of love, romance!”
Henry is one of seven patients profiled in the documentary “Alive Inside,” a heartwarming look at the power of music to help those in nursing homes.
Read all about it HERE
visit us at AlzheimerHeadlines.com
News from the web:
New research in humans reveals that the so-called FKBP52 protein may prevent the Tau protein from turning pathogenic. This may prove significant for the development of new Alzheimer’s drugs and for detecting the disease before the onset of clinical symptoms.
A study published online March 21 in the Journal of Alzheimer’s Disease, for the first time demonstrates that the FKBP52 protein, discovered by Prof. Etienne BAULIEU twenty years ago, may prevent hyperphosphorylation of Tau protein, which has been shown to characterise a number of cerebral neurodegenerative diseases, including Alzheimer’s Disease (AD).
This work has been carried out by Professor Etienne Baulieu and his research team at Inserm (National Institute for medical research in France) with the support of philanthropists who help the Institut Baulieu, based in France.
Read all about it HERE
visit us at AlzheimerHeadlines.com
News from the web:
More than five million Americans are currently living with Alzheimer’s disease. It takes an average of 30 months from the time family members notice the first symptoms of dementia until the person is diagnosed with Alzheimer’s. There are several reasons for this, but one of the principal ones is that family members hesitate to take their loved one to a doctor, fearing that the diagnosis will in fact turn out to be Alzheimer’s.
Alzheimer’s is, above all, an insidious illness. It begins with very mild symptoms — things we all do from time to time, such as forgetting to turn off the stove, temporarily forgetting an acquaintance’s name, or misplacing the car keys. But for the person with dementia, these events will become more frequent, and with time more serious symptoms will appear.
Read all about it HERE
visit us at AlzheimerHeadlines.com
News from the web:
Thousands of patients with advanced Alzheimer’s disease could benefit from drugs, research suggests.
A study in the the New England Journal of Medicine found that patients who stayed on the dementia drug Aricept had a slower decline in their memory.
The drug tends not to be prescribed once sufferers progress beyond moderate symptoms.
Medicines regulator NICE said its guidelines supported continuing treatment where there were benefits.
The patent for the medicine Aricept, which is used to treat Alzheimer’s disease, expired recently. Much cheaper versions under the generic name donepezil are already available for about £12 a month.
Read all about it HERE
visit us at AlzheimerHeadlines.com